Vaccination with hybrids of tumor and dendritic cells induces tumor‐specific T‐cell and clinical responses in melanoma stage III and IV patients
Hybrid cell vaccination was developed as therapeutic approach that aims at stimulating tumor‐specific cytotoxic T‐cell responses in cancer patients using hybrids of autologous tumor and allogeneic dendritic cells. We tested this concept and the efficacy of the vaccines in inducing clinical and immun...
Gespeichert in:
| Veröffentlicht in: | International journal of cancer 2004-07, Vol.110 (5), p.730-740 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 740 |
|---|---|
| container_issue | 5 |
| container_start_page | 730 |
| container_title | International journal of cancer |
| container_volume | 110 |
| creator | Trefzer, Uwe Herberth, Gunda Wohlan, Karolina Milling, Annett Thiemann, Max Sherev, Tumenjargal Sparbier, Katrin Sterry, Wolfram Walden, Peter |
| description | Hybrid cell vaccination was developed as therapeutic approach that aims at stimulating tumor‐specific cytotoxic T‐cell responses in cancer patients using hybrids of autologous tumor and allogeneic dendritic cells. We tested this concept and the efficacy of the vaccines in inducing clinical and immunologic responses in a clinical trial with melanoma stage III and IV patients. Of the 17 patients evaluated, 1 experienced a complete response, 1 a partial response and 6 stable disease with remarkably long survival times. In 11 of 14 patients analyzed, high‐frequency T‐cell responses to various tumor‐associated T‐cell epitope were induced and detectable in the peripheral blood. These immune responses were detected in clinical response patients as well as nonresponders. Failures of clinical responses in all the cases investigated correlated with loss of antigen expression and presentation. Hybrid cell vaccination thus proves effective in inducing tumor‐specific T‐cell responses in cancer patients. © 2004 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/ijc.20191 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71932330</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71932330</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3871-f2b6b62bd6725b35d951b4e302860b7369b52f4174b64bc004812e12e7d534143</originalsourceid><addsrcrecordid>eNqF0c1qFTEYBuAgij1WF96AZCW4mDZffs8s5VB1pOCmdjvkb2zKTGZMZihn5yW46BX2Ssw5c8CVCIEQvicvH7wIvQVyAYTQy3BvLyiBGp6hDZBaVYSCeI42ZUYqBUyeoVc53xMCIAh_ic5AAJdCsg16vNXWhqjnMEb8EOY7fLc3KbiMxw7PyzAmrKPDzkeXwhwstr7vMw7RLdbnVTz9-p0nb0NXxjflcSDHX7YPMVjd4-TzNMbsDx_x4Hsdx0HjPOsfHjdNc8TNLZ7KGj7O-TV60ek--zen-xx9_3R1s_tSXX_73Ow-XleWbRVUHTXSSGqcVFQYJlwtwHDPCN1KYhSTtRG046C4kdxYQvgWqC9HOcE4cHaO3q-5Uxp_Lj7P7RDyYXsd_bjkVkHNKGPkvxBUrUhdQ4EfVmjTmHPyXTulMOi0b4G0h67a0lV77KrYd6fQxQze_ZWncgq4XMFD6P3-30lt83W3Rv4BSymgCQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17970991</pqid></control><display><type>article</type><title>Vaccination with hybrids of tumor and dendritic cells induces tumor‐specific T‐cell and clinical responses in melanoma stage III and IV patients</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Trefzer, Uwe ; Herberth, Gunda ; Wohlan, Karolina ; Milling, Annett ; Thiemann, Max ; Sherev, Tumenjargal ; Sparbier, Katrin ; Sterry, Wolfram ; Walden, Peter</creator><creatorcontrib>Trefzer, Uwe ; Herberth, Gunda ; Wohlan, Karolina ; Milling, Annett ; Thiemann, Max ; Sherev, Tumenjargal ; Sparbier, Katrin ; Sterry, Wolfram ; Walden, Peter</creatorcontrib><description>Hybrid cell vaccination was developed as therapeutic approach that aims at stimulating tumor‐specific cytotoxic T‐cell responses in cancer patients using hybrids of autologous tumor and allogeneic dendritic cells. We tested this concept and the efficacy of the vaccines in inducing clinical and immunologic responses in a clinical trial with melanoma stage III and IV patients. Of the 17 patients evaluated, 1 experienced a complete response, 1 a partial response and 6 stable disease with remarkably long survival times. In 11 of 14 patients analyzed, high‐frequency T‐cell responses to various tumor‐associated T‐cell epitope were induced and detectable in the peripheral blood. These immune responses were detected in clinical response patients as well as nonresponders. Failures of clinical responses in all the cases investigated correlated with loss of antigen expression and presentation. Hybrid cell vaccination thus proves effective in inducing tumor‐specific T‐cell responses in cancer patients. © 2004 Wiley‐Liss, Inc.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.20191</identifier><identifier>PMID: 15146563</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Cancer Vaccines ; CD8-Positive T-Lymphocytes - metabolism ; Cell Culture Techniques - methods ; clinical trial ; Dendritic Cells - cytology ; Epitopes - chemistry ; Female ; Flow Cytometry ; Humans ; Hybrid Cells ; immune escape ; immune monitoring ; Immunohistochemistry ; Leukocytes, Mononuclear - metabolism ; Male ; melanoma ; Melanoma - metabolism ; Middle Aged ; Neoplasms - metabolism ; Phenotype ; Skin Neoplasms - metabolism ; T cell ; Time Factors ; Tumor Cells, Cultured ; tumor vaccine</subject><ispartof>International journal of cancer, 2004-07, Vol.110 (5), p.730-740</ispartof><rights>Copyright © 2004 Wiley‐Liss, Inc.</rights><rights>Copyright 2004 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3871-f2b6b62bd6725b35d951b4e302860b7369b52f4174b64bc004812e12e7d534143</citedby><cites>FETCH-LOGICAL-c3871-f2b6b62bd6725b35d951b4e302860b7369b52f4174b64bc004812e12e7d534143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.20191$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.20191$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15146563$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Trefzer, Uwe</creatorcontrib><creatorcontrib>Herberth, Gunda</creatorcontrib><creatorcontrib>Wohlan, Karolina</creatorcontrib><creatorcontrib>Milling, Annett</creatorcontrib><creatorcontrib>Thiemann, Max</creatorcontrib><creatorcontrib>Sherev, Tumenjargal</creatorcontrib><creatorcontrib>Sparbier, Katrin</creatorcontrib><creatorcontrib>Sterry, Wolfram</creatorcontrib><creatorcontrib>Walden, Peter</creatorcontrib><title>Vaccination with hybrids of tumor and dendritic cells induces tumor‐specific T‐cell and clinical responses in melanoma stage III and IV patients</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Hybrid cell vaccination was developed as therapeutic approach that aims at stimulating tumor‐specific cytotoxic T‐cell responses in cancer patients using hybrids of autologous tumor and allogeneic dendritic cells. We tested this concept and the efficacy of the vaccines in inducing clinical and immunologic responses in a clinical trial with melanoma stage III and IV patients. Of the 17 patients evaluated, 1 experienced a complete response, 1 a partial response and 6 stable disease with remarkably long survival times. In 11 of 14 patients analyzed, high‐frequency T‐cell responses to various tumor‐associated T‐cell epitope were induced and detectable in the peripheral blood. These immune responses were detected in clinical response patients as well as nonresponders. Failures of clinical responses in all the cases investigated correlated with loss of antigen expression and presentation. Hybrid cell vaccination thus proves effective in inducing tumor‐specific T‐cell responses in cancer patients. © 2004 Wiley‐Liss, Inc.</description><subject>Adult</subject><subject>Aged</subject><subject>Cancer Vaccines</subject><subject>CD8-Positive T-Lymphocytes - metabolism</subject><subject>Cell Culture Techniques - methods</subject><subject>clinical trial</subject><subject>Dendritic Cells - cytology</subject><subject>Epitopes - chemistry</subject><subject>Female</subject><subject>Flow Cytometry</subject><subject>Humans</subject><subject>Hybrid Cells</subject><subject>immune escape</subject><subject>immune monitoring</subject><subject>Immunohistochemistry</subject><subject>Leukocytes, Mononuclear - metabolism</subject><subject>Male</subject><subject>melanoma</subject><subject>Melanoma - metabolism</subject><subject>Middle Aged</subject><subject>Neoplasms - metabolism</subject><subject>Phenotype</subject><subject>Skin Neoplasms - metabolism</subject><subject>T cell</subject><subject>Time Factors</subject><subject>Tumor Cells, Cultured</subject><subject>tumor vaccine</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0c1qFTEYBuAgij1WF96AZCW4mDZffs8s5VB1pOCmdjvkb2zKTGZMZihn5yW46BX2Ssw5c8CVCIEQvicvH7wIvQVyAYTQy3BvLyiBGp6hDZBaVYSCeI42ZUYqBUyeoVc53xMCIAh_ic5AAJdCsg16vNXWhqjnMEb8EOY7fLc3KbiMxw7PyzAmrKPDzkeXwhwstr7vMw7RLdbnVTz9-p0nb0NXxjflcSDHX7YPMVjd4-TzNMbsDx_x4Hsdx0HjPOsfHjdNc8TNLZ7KGj7O-TV60ek--zen-xx9_3R1s_tSXX_73Ow-XleWbRVUHTXSSGqcVFQYJlwtwHDPCN1KYhSTtRG046C4kdxYQvgWqC9HOcE4cHaO3q-5Uxp_Lj7P7RDyYXsd_bjkVkHNKGPkvxBUrUhdQ4EfVmjTmHPyXTulMOi0b4G0h67a0lV77KrYd6fQxQze_ZWncgq4XMFD6P3-30lt83W3Rv4BSymgCQ</recordid><startdate>20040710</startdate><enddate>20040710</enddate><creator>Trefzer, Uwe</creator><creator>Herberth, Gunda</creator><creator>Wohlan, Karolina</creator><creator>Milling, Annett</creator><creator>Thiemann, Max</creator><creator>Sherev, Tumenjargal</creator><creator>Sparbier, Katrin</creator><creator>Sterry, Wolfram</creator><creator>Walden, Peter</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20040710</creationdate><title>Vaccination with hybrids of tumor and dendritic cells induces tumor‐specific T‐cell and clinical responses in melanoma stage III and IV patients</title><author>Trefzer, Uwe ; Herberth, Gunda ; Wohlan, Karolina ; Milling, Annett ; Thiemann, Max ; Sherev, Tumenjargal ; Sparbier, Katrin ; Sterry, Wolfram ; Walden, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3871-f2b6b62bd6725b35d951b4e302860b7369b52f4174b64bc004812e12e7d534143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Cancer Vaccines</topic><topic>CD8-Positive T-Lymphocytes - metabolism</topic><topic>Cell Culture Techniques - methods</topic><topic>clinical trial</topic><topic>Dendritic Cells - cytology</topic><topic>Epitopes - chemistry</topic><topic>Female</topic><topic>Flow Cytometry</topic><topic>Humans</topic><topic>Hybrid Cells</topic><topic>immune escape</topic><topic>immune monitoring</topic><topic>Immunohistochemistry</topic><topic>Leukocytes, Mononuclear - metabolism</topic><topic>Male</topic><topic>melanoma</topic><topic>Melanoma - metabolism</topic><topic>Middle Aged</topic><topic>Neoplasms - metabolism</topic><topic>Phenotype</topic><topic>Skin Neoplasms - metabolism</topic><topic>T cell</topic><topic>Time Factors</topic><topic>Tumor Cells, Cultured</topic><topic>tumor vaccine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Trefzer, Uwe</creatorcontrib><creatorcontrib>Herberth, Gunda</creatorcontrib><creatorcontrib>Wohlan, Karolina</creatorcontrib><creatorcontrib>Milling, Annett</creatorcontrib><creatorcontrib>Thiemann, Max</creatorcontrib><creatorcontrib>Sherev, Tumenjargal</creatorcontrib><creatorcontrib>Sparbier, Katrin</creatorcontrib><creatorcontrib>Sterry, Wolfram</creatorcontrib><creatorcontrib>Walden, Peter</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Trefzer, Uwe</au><au>Herberth, Gunda</au><au>Wohlan, Karolina</au><au>Milling, Annett</au><au>Thiemann, Max</au><au>Sherev, Tumenjargal</au><au>Sparbier, Katrin</au><au>Sterry, Wolfram</au><au>Walden, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccination with hybrids of tumor and dendritic cells induces tumor‐specific T‐cell and clinical responses in melanoma stage III and IV patients</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2004-07-10</date><risdate>2004</risdate><volume>110</volume><issue>5</issue><spage>730</spage><epage>740</epage><pages>730-740</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><abstract>Hybrid cell vaccination was developed as therapeutic approach that aims at stimulating tumor‐specific cytotoxic T‐cell responses in cancer patients using hybrids of autologous tumor and allogeneic dendritic cells. We tested this concept and the efficacy of the vaccines in inducing clinical and immunologic responses in a clinical trial with melanoma stage III and IV patients. Of the 17 patients evaluated, 1 experienced a complete response, 1 a partial response and 6 stable disease with remarkably long survival times. In 11 of 14 patients analyzed, high‐frequency T‐cell responses to various tumor‐associated T‐cell epitope were induced and detectable in the peripheral blood. These immune responses were detected in clinical response patients as well as nonresponders. Failures of clinical responses in all the cases investigated correlated with loss of antigen expression and presentation. Hybrid cell vaccination thus proves effective in inducing tumor‐specific T‐cell responses in cancer patients. © 2004 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>15146563</pmid><doi>10.1002/ijc.20191</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7136 |
| ispartof | International journal of cancer, 2004-07, Vol.110 (5), p.730-740 |
| issn | 0020-7136 1097-0215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71932330 |
| source | MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Cancer Vaccines CD8-Positive T-Lymphocytes - metabolism Cell Culture Techniques - methods clinical trial Dendritic Cells - cytology Epitopes - chemistry Female Flow Cytometry Humans Hybrid Cells immune escape immune monitoring Immunohistochemistry Leukocytes, Mononuclear - metabolism Male melanoma Melanoma - metabolism Middle Aged Neoplasms - metabolism Phenotype Skin Neoplasms - metabolism T cell Time Factors Tumor Cells, Cultured tumor vaccine |
| title | Vaccination with hybrids of tumor and dendritic cells induces tumor‐specific T‐cell and clinical responses in melanoma stage III and IV patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T03%3A47%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccination%20with%20hybrids%20of%20tumor%20and%20dendritic%20cells%20induces%20tumor%E2%80%90specific%20T%E2%80%90cell%20and%20clinical%20responses%20in%20melanoma%20stage%20III%20and%20IV%20patients&rft.jtitle=International%20journal%20of%20cancer&rft.au=Trefzer,%20Uwe&rft.date=2004-07-10&rft.volume=110&rft.issue=5&rft.spage=730&rft.epage=740&rft.pages=730-740&rft.issn=0020-7136&rft.eissn=1097-0215&rft_id=info:doi/10.1002/ijc.20191&rft_dat=%3Cproquest_cross%3E71932330%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17970991&rft_id=info:pmid/15146563&rfr_iscdi=true |